Viewing data from:

VONJO

NDA

PACRITINIB CITRATE | N208712 | SOBI INC

1 strength3 unique patents2 unique exclusivities

Patent Timeline

3 unique patents, 2 exclusivities by expiration date

Active (3)TodayExclusivity

2027

2028

2029

2030

Today

8153632

Jan. 17, 2029

8980873

Mar. 25, 2030

9573964

May. 5, 2028

NCE

Feb. 28, 2027

ODE-397

Feb. 28, 2029

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Medicare Part D Spending

CMS annual spending data for Vonjo (2023)

Total Spending

$92.5M

Total Claims

4,256

Beneficiaries

950

Avg Cost/Unit

$207.25

Spending Trend

$37.7M(2022)→$92.5M(2023)

YoY Change:+15.9%

5yr CAGR:+15.9%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain1 active DMF

1 active API supplier hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

TAPI NL BVPACRITINIB CITRATE

DMF 415132025

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

6 letters from Drugs@FDA

Date	Submission	Document
Mar 20, 2026	SUPPL -7	View Letter (PDF)
Oct 3, 2025	SUPPL -4	View Letter (PDF)
Aug 26, 2025	SUPPL -6	View Letter (PDF)
Nov 13, 2024	SUPPL -3	View Letter (PDF)
Aug 16, 2023	SUPPL -1	View Letter (PDF)
Mar 1, 2022	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — EQ 100MG BASE

RLD

3 patents2 exclusivities▴

CAPSULE;ORAL | Approved: Feb 28, 2022

Patents (3)

Patent #	Expiration	PED	Drug Substance	Drug Product	Delist
8153632	Jan 17, 2029	—	Yes	Yes	—
8980873	Mar 25, 2030	—	Yes	Yes	—
9573964	May 5, 2028	—	—	—	—

Exclusivities (2)

Code	Date	Status
NCE	Feb 28, 2027	< 1 year
ODE-397	Feb 28, 2029	Active